NF2 alterations predominated in cerebral convexity (29/58; 50%) and spinal tumors (5/7; 71%), while TRAKLS mutations were enriched in skull base tumors (15/22; 68%) (Figure 4). The gene discussed is NF2; the disease is skull base neoplasm.